If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Tomoko Seki is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 4 Similar Profiles
Breast Neoplasms Medicine & Life Sciences
Neoadjuvant Therapy Medicine & Life Sciences
eribulin Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
olanzapine Medicine & Life Sciences
Simple Mastectomy Medicine & Life Sciences
Safety Medicine & Life Sciences
Anthracyclines Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2014 2019

  • 68 Citations
  • 5 h-Index
  • 8 Article
  • 1 Review article

Optimal use of anthracycline-free perioperative chemotherapy in HER2-positive breast cancer patients

Watanuki, R., Hayashida, T., Kawai, Y., Kikuchi, M., Nakashoji, A., Yokoe, T., Toyota, T., Seki, T., Takahashi, M. & Kitagawa, Y., 2019 Jan 1, In : International Journal of Clinical Oncology.

Research output: Contribution to journalArticle

Anthracyclines
Breast Neoplasms
Drug Therapy
Adjuvant Chemotherapy
Disease-Free Survival

Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis

Yokoe, T., Hayashida, T., Nagayama, A., Nakashoji, A., Maeda, H., Seki, T., Takahashi, M., Takano, T., Abe, T. & Kitagawa, Y., 2018 Jan 1, (Accepted/In press) In : Oncologist.

Research output: Contribution to journalArticle

olanzapine
Antiemetics
Nausea
Dexamethasone
Vomiting
1 Citation (Scopus)

IgG4-related mastopathy: A case report and literature review

Yokoe, T., Hayashida, T., Kikuchi, M., Watanuki, R., Nakashoji, A., Maeda, H., Toyota, T., Seki, T., Takahashi, M., Iwasaki, E., Mikami, S., Kameyama, K. & Kitagawa, Y., 2018 Aug 1, In : Clinical Case Reports. 6, 8, p. 1549-1553 5 p.

Research output: Contribution to journalArticle

Breast
Immunoglobulin G
Needle Biopsy
Glucocorticoids
Neoplasms
1 Citation (Scopus)

Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: A multicenter, single-arm trial

Hayashida, T., Jinno, H., Mori, K., Sato, H., Matsui, A., Sakurai, T., Hattori, H., Takayama, S., Wada, M., Takahashi, M., Seki, H., Seki, T., Nagayama, A., Matsumoto, A. & Kitagawa, Y., 2018 Jun 28, In : BMC Cancer. 18, 1, 701.

Research output: Contribution to journalArticle

eribulin
Breast Neoplasms
Confidence Intervals
Safety
Therapeutics
8 Citations (Scopus)

The updated network meta-analysis of neoadjuvant therapy for HER2-positive breast cancer

Nakashoji, A., Hayashida, T., Yokoe, T., Maeda, H., Toyota, T., Kikuchi, M., Watanuki, R., Nagayama, A., Seki, T., Takahashi, M., Abe, T. & Kitagawa, Y., 2018 Jan 1, In : Cancer Treatment Reviews. 62, p. 9-17 9 p.

Research output: Contribution to journalReview article

Neoadjuvant Therapy
Breast Neoplasms
Statistical Models
Network Meta-Analysis
human ERBB2 protein